Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Degludec

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 7Ryzodeg

    02 8Tresiba

    03 7Xultophy

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Xultophy

    Insulin Degludec, Insulin Aspart

    arrow
    AACR Annual meeting
    Not Confirmed

    Brand Name : Xultophy

    Denmark
    arrow
    AACR Annual meeting
    Not Confirmed

    Novo Nordisk

    Insulin Degludec, Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 398

    2019 Revenue in Millions : 359

    Growth (%) : 11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Tresiba

    Insulin Degludec, Insulin Aspart

    arrow
    AACR Annual meeting
    Not Confirmed

    Brand Name : Tresiba

    Denmark
    arrow
    AACR Annual meeting
    Not Confirmed

    Novo Nordisk

    Insulin Degludec, Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 1,459

    2019 Revenue in Millions : 1,506

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Ryzodeg

    Insulin Degludec, Insulin Aspart

    arrow
    AACR Annual meeting
    Not Confirmed

    Brand Name : Ryzodeg

    Denmark
    arrow
    AACR Annual meeting
    Not Confirmed

    Novo Nordisk

    Insulin Degludec, Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 210

    2019 Revenue in Millions : 162

    Growth (%) : 30

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Ryzodeg

    Insulin Degludec, Insulin Aspart

    arrow
    AACR Annual meeting
    Not Confirmed

    Brand Name : Ryzodeg

    Denmark
    arrow
    AACR Annual meeting
    Not Confirmed

    Novo Nordisk

    Insulin Degludec, Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 261

    2020 Revenue in Millions : 207

    Growth (%) : 33

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Tresiba

    Insulin Degludec, Insulin Aspart

    arrow
    AACR Annual meeting
    Not Confirmed

    Brand Name : Tresiba

    Denmark
    arrow
    AACR Annual meeting
    Not Confirmed

    Novo Nordisk

    Insulin Degludec, Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 1,483

    2020 Revenue in Millions : 1,435

    Growth (%) : 8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Xultophy

    Insulin Degludec, Insulin Aspart

    arrow
    AACR Annual meeting
    Not Confirmed

    Brand Name : Xultophy

    Denmark
    arrow
    AACR Annual meeting
    Not Confirmed

    Novo Nordisk

    Insulin Degludec, Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 405

    2020 Revenue in Millions : 391

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Tresiba

    Insulin Degludec, Insulin Aspart

    arrow
    AACR Annual meeting
    Not Confirmed

    Brand Name : Tresiba

    Denmark
    arrow
    AACR Annual meeting
    Not Confirmed

    Novo Nordisk

    Insulin Degludec, Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 1,364

    2021 Revenue in Millions : 1,483

    Growth (%) : -8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Xultophy

    Insulin Degludec, Insulin Aspart

    arrow
    AACR Annual meeting
    Not Confirmed

    Brand Name : Xultophy

    Denmark
    arrow
    AACR Annual meeting
    Not Confirmed

    Novo Nordisk

    Insulin Degludec, Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 410

    2021 Revenue in Millions : 405

    Growth (%) : 1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Ryzodeg

    Insulin Degludec, Insulin Aspart

    arrow
    AACR Annual meeting
    Not Confirmed

    Brand Name : Ryzodeg

    Denmark
    arrow
    AACR Annual meeting
    Not Confirmed

    Novo Nordisk

    Insulin Degludec, Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 421

    2021 Revenue in Millions : 261

    Growth (%) : 62

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Xultophy

    Insulin Degludec, Insulin Aspart

    arrow
    AACR Annual meeting
    Not Confirmed

    Brand Name : Xultophy

    Denmark
    arrow
    AACR Annual meeting
    Not Confirmed

    Novo Nordisk

    Insulin Degludec, Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2023 Revenue in Millions : 468

    2022 Revenue in Millions : 410

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.